Hanmi Pharm stock: BioMarin licenses Fabry therapy candidate
Published on 10/30/2026 at 02:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLicense deal expands Hanmi's pipeline
- BioMarin will lead later development, manufacturing and commercialization outside Korea.
- The candidate is being evaluated in a Phase 1/2 clinical trial and is designed for subcutaneous dosing.
- Hanmi and GC Biopharma retain commercialization rights in Korea and are eligible for tiered royalties.
Hanmi Pharm and GC Biopharma have entered into an exclusive license agreement with BioMarin for the investigational Fabry disease therapy HM15421/GC1134A. BioMarin announced the agreement on October 29, 2026.
Terms and development responsibilities
BioMarin will pay an upfront amount of USD 70 million. Hanmi and GC Biopharma are jointly eligible for up to USD 405 million in additional development and commercial milestone payments, as well as tiered royalties on net sales.
The license covers worldwide rights except Korea. BioMarin will assume responsibility for subsequent clinical development, manufacturing and commercialization outside Korea after the ongoing Phase 1/2 study. Hanmi and GC Biopharma will retain commercialization rights in Korea.
Clinical-stage Fabry candidate
HM15421/GC1134A is a long-acting enzyme replacement therapy based on recombinant alpha-galactosidase A. It is designed to extend half-life and improve stability compared with currently available enzyme replacement therapies, supporting administration under the skin rather than through an intravenous infusion.
BioMarin said the candidate is being studied in a Phase 1/2 clinical trial and received Orphan Drug Designation from the U.S. Food and Drug Administration in 2024. Preclinical studies showed differentiated results across measures related to renal function, vascular health and the peripheral nervous system, according to the company.
Hanmi Pharm at a glance
- Agreement: Exclusive license with BioMarin
- Candidate: HM15421/GC1134A
- Indication: Fabry disease
- Development stage: Phase 1/2 clinical trial
- Upfront payment: USD 70 million
- Potential milestones: Up to USD 405 million
The broader market context is available in current market reports.
For investors, the agreement adds a clinical-stage partnering event to Hanmi's pipeline. The milestone component remains dependent on future development and commercialization progress, while the therapy's commercial prospects will depend on clinical results and regulatory decisions.
